ArticleScientific reports2026
The role of the α7 nicotinic acetylcholine receptor in promoting M2 macrophage polarization at inflammatory sites.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Nicotinic Acetylcholine Receptor-Macrophage Axis in Merkel Cell Carcinoma: Evidence, Limitations, and Therapeutic Hypotheses.International journal of molecular sciences · 2026Review
- Vagus nerve as the hub in peripheral immune-inflammatory response: implications for related therapeutic drugs.Molecular biology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The α7 nicotinic acetylcholine receptor (α7nAChR) on macrophages exerts anti-inflammatory effects by suppressing the JAK/STAT and NF-κB pathways. Although the role of α7nAChR in immunoregulatory mechanisms in "individual" macrophages is established, studies on α7nAChR in an "overall population" of macrophages, including M1/M2 polarity, remain limited. Therefore, we examined the role of α7nAChR in M1/M2 polarity in inflammation. We generated peritonitis mouse models via LPS treatment and sterile intestinal manipulation in wild-type and α7nAChR-deficient mice. M1/M2 macrophage polarization was measured using PCR and flow cytometry. THP-1 and human peripheral blood mononuclear cells (hPBMC)-derived monocytes were treated with the α7nAChR agonist PNU-282987 during differentiation into M1/M2 macrophages. α7nAChR deficiency upregulated mRNA expression of the M1 marker and downregulated the M2 marker in a peritoneal cell population. Flow cytometry analysis revealed that the proportion of M2 macrophages in the peritoneal cell population decreased in α7nAChR-deficient mice in both models. In splenectomized LPS-treated wild-type mice, the proportion of M2 macrophages in the peritoneal cell population was reduced compared to that in sham-operated LPS-treated mice. The M2 marker CD206 and IL10 were upregulated in PNU-282987-treated THP-1 and hPBMC-derived macrophages. These results revealed that α7nAChR exerted M2-enhancing effects with the mechanism suggestively acting in the spleen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.